Group 1 - The total salary of A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - Among the A-share listed companies, 1,144 secretaries earned over 1 million yuan annually, accounting for over 21% [1] - The age distribution of secretaries shows that those aged 40-50 constitute 42%, while those over 50 account for 29%, and those under 40 make up 26% [1] Group 2 - The educational background of secretaries indicates that 5% have an associate degree, 42% hold a bachelor's degree, 49% possess a master's degree, and 4% have a doctoral degree, with over half holding a master's degree or higher [3] - Only three secretaries hold a doctoral degree, specifically from Yiling Pharmaceutical, Kunming Pharmaceutical Group, and Jinhua Co., Ltd. [3] Group 3 - The average annual salary of secretaries in A-share listed Chinese medicine companies is 742,400 yuan, with 39% earning below 500,000 yuan, 42% earning between 500,000 and 1 million yuan, and 15% earning between 1 million and 2 million yuan [5] - The top five highest-paid secretaries are from China Resources Sanjiu, Jichuan Pharmaceutical, Tianjin Pharmaceutical, Yiling Pharmaceutical, and Yibai Pharmaceutical, with salaries ranging from 1.3935 million to 2.5587 million yuan [7] Group 4 - There is significant variation in the number of investor receptions among listed companies, with 59% receiving fewer than 10 times a year, while 3% received between 300 and 1,000 times [9] - The five companies with the highest number of investor receptions are Zoli Pharmaceutical, Qizheng Pharmaceutical, Yunnan Baiyao, Jinghua Pharmaceutical, and Pianzihuang, with receptions ranging from 207 to 410 times [9]

Core Insights - The report highlights that the total salary for A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - A total of 1,144 company secretaries earn over 1 million yuan annually, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary for company secretaries in the A-share traditional Chinese medicine sector is 742,400 yuan [5] - The distribution of salaries is as follows: below 500,000 yuan (27 individuals, 39%), between 500,000-1,000,000 yuan (29 individuals, 42%), between 1,000,000-2,000,000 yuan (10 individuals, 15%), between 2,000,000-3,000,000 yuan (2 individuals, 3%), and above 3,000,000 yuan (1 individual, 1%) [5] Age and Educational Background - The age distribution of company secretaries shows that those aged 40-50 constitute 42%, while those over 50 account for 29%, and those under 40 make up 26% [1] - In terms of educational qualifications, 5% have an associate degree, 42% hold a bachelor's degree, 49% possess a master's degree, and 4% have a doctoral degree, with over half of the secretaries holding a master's degree or higher [3] Top Earners and Investor Relations - The top five highest-paid company secretaries are: - Xing Jian from China Resources Sanjiu (2.5587 million yuan) - Cao Wei from Jichuan Pharmaceutical (2.4107 million yuan) - Yu Jie from Tian Shi Li (2.525 million yuan) - Wu Rui from Yiling Pharmaceutical (1.89 million yuan) - Jiang Xianhong from Yibai Pharmaceutical (1.3935 million yuan) [7] - The frequency of investor meetings varies significantly among companies, with 41 companies hosting fewer than 10 meetings annually (59%), 17 companies holding 10-100 meetings (25%), 9 companies conducting 100-300 meetings (13%), and 2 companies having 300-1000 meetings (3%) [7] Most Active Companies in Investor Relations - The five companies with the highest number of investor meetings are: - Zoli Pharmaceutical (410 meetings) - Qizheng Tibetan Medicine (404 meetings) - Yunnan Baiyao (298 meetings) - Jinghua Pharmaceutical (221 meetings) - Pian Zai Huang (207 meetings) [9]

Core Insights - The report highlights that the total salary for A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - A total of 1,144 company secretaries earn over 1 million yuan annually, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary for company secretaries in the A-share traditional Chinese medicine sector is 742,400 yuan [5] - The distribution of salaries is as follows: - Below 500,000 yuan: 27 individuals (39%) - 500,000-1,000,000 yuan: 29 individuals (42%) - 1,000,000-2,000,000 yuan: 10 individuals (15%) - 2,000,000-3,000,000 yuan: 2 individuals (3%) - Above 3,000,000 yuan: 1 individual (1%) [5] Age and Educational Background - The age distribution of company secretaries shows that those aged 40-50 constitute 42%, while those over 50 account for 29%, and those under 40 make up 26% [1] - The educational background indicates that 5% have an associate degree, 42% hold a bachelor's degree, 49% possess a master's degree, and 4% have a doctoral degree, with over half of the secretaries holding a master's degree or higher [3] Top Earning Company Secretaries - The top five highest-paid company secretaries are: - Xing Jian from China Resources Sanjiu: 2.5587 million yuan - Cao Wei from Jichuan Pharmaceutical: 2.4107 million yuan - Yu Jie from Tianjin Tasly: 2.525 million yuan - Wu Rui from Yiling Pharmaceutical: 1.89 million yuan - Jiang Xianhong from Yibai Pharmaceutical: 1.3935 million yuan - Their tenure at the companies ranges from less than 1 year to 15 years [7] Investor Engagement - There is significant variation in the number of investor meetings held by companies: - Less than 10 meetings: 41 companies (59%) - 10-100 meetings: 17 companies (25%) - 100-300 meetings: 9 companies (13%) - 300-1000 meetings: 2 companies (3%) [7] - The five companies with the highest number of investor meetings are: - Zoli Pharmaceutical: 410 meetings - Qizheng Pharmaceutical: 404 meetings - Yunnan Baiyao: 298 meetings - Jinghua Pharmaceutical: 221 meetings - Pianzihuang: 207 meetings [9]

专题：专题|2024年度A股董秘数据报告：1144位董秘年薪超百万 占比超21% 董秘作为连接投资者与上市公司的"桥梁"，在上市公司资本运作中发挥着关键作用。新浪财经《2024年 度A股董秘数据报告》显示，2024年A股上市公司董秘薪酬合计达40.86亿元，平均年薪75.43万元。 分行业来看，统计数据显示，A股共有69家上市中药公司，董事会秘书聘任总体情况如下（部分统计口 径剔除无效数据）。 从董秘的年龄分布来看，介于40-50岁的董秘是市场的中坚力量，占比达到42%；50岁以上的董秘占比 为29%；小于40岁的董秘群体占比为26%。其中，最年轻的上市公司董秘年仅32岁，为特一药业的许紫 兰。 从董秘的学历分布看，拥有大专、本科、硕士、博士学历的董秘占比分别为5%、42%、49%、4%，硕 士及以上学历董秘占比已超过半数。其中，获得博士学历的董秘仅三人，分别为以岭药业（维权）的吴 瑞、昆药集团的张梦珣、金花股份（维权）的张朝阳。 从薪酬分布看，A股中药上市公司董秘年薪平均值为74.24万元。经统计，处于50万以下、50万-100万、 100万-200万、200万-300万、300万以上各区间的人数分别为27 ...

港股医疗健康板块也逐渐开始回暖，更多企业涌向港交所申请IPO，其中不乏独角兽级别的企业——去 年12月，微医时隔三年重启IPO；今年5月，英矽智能三度递表；今年6月，镁信健康也赴港申请IPO。 过去十年间，中国医疗投资市场经历了巨大的起伏，从2015年行业融资额暴增，开启医疗投资的"元 年"，到2021年达到3800余亿元的融资峰值，而后行业又进入沉寂。 在这一波波投资热潮里，医疗健康行业里产生了数百家估值超十亿美元的医疗独角兽，分布在数字医 疗、AI制药、手术机器人、互联网医院、慢病管理平台等各个领域。大家都一度风华正茂，头顶着技 术创新、政策蓝海或美好的商业预期等各种光环，在不断加注的融资中走到独角兽的体量。幸运几乎是 这一批医疗独角兽的共同特征，巨大的外部机遇让它们以极低的时间成本将成就最大化。 但也正是在这一轮又一轮的资本热潮中，行业的"堰塞湖"悄然形成：高估值、大投入、慢转化。在漫漫 创业长路里，许多项目因为不确定的商业回报兑现、冗长的客户转化周期与故事的一再切换，让公司处 于持续亏损，通过上市来兑现"估值"变得遥遥无期，甚至要面临生存危机。医疗行业的一级市场漂悬着 众多的"梦"，太多创始人、高管团 ...

证券代码：600535 证券简称：天士力 编号：临 2025-047 号 天士力医药集团股份有限公司 关于员工持股计划存续期届满暨终止的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 天士力医药集团股份有限公司（以下简称"公司"）第一期员工持股计划、 第二期员工持股计划存续期于 2025 年 7 月 24 日届满，根据中国证券监督管理委 员会《关于上市公司实施员工持股计划试点的指导意见》《上海证券交易所上市 公司自律监管指引第 1 号——规范运作》等规定，现将相关情况公告如下： 一、公司员工持股计划基本情况 （详见公司分别于 2018 年 5 月 19 日和 2018 年 8 月 24 日披露的 《2018 年第二次临时股东大会决议公告》和《第二期员工持股计划进展暨完成股票购买 的公告》）。 公司第二期员工持股计划根据《天士力医药集团股份有限公司第二期员工持 股计划》，授权董事会决定本次员工持股计划的存续期的延长。公司召开了第二 期员工持股计划历次持有人会议及董事会相关会议，审议通过了《关于第二期员 工持股计划存续 ...

天士力医药集团股份有限公司 关于员工持股计划存续期届满暨终止的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 天士力医药集团股份有限公司（以下简称"公司"）第一期员工持股计划、 第二期员工持股计划存续期于 2025 年 7 月 24 日届满，根据中国证券监督管理委 员会《关于上市公司实施员工持股计划试点的指导意见》《上海证券交易所上市 公司自律监管指引第 1 号——规范运作》等规定，现将相关情况公告如下： 一、公司员工持股计划基本情况 1、公司第一期员工持股计划 2017 年 4 月 25 日，公司 2016 年年度股东大会审议通过了《公司第一期员 工持股计划（草案）及摘要》等相关议案。截至 2017 年 6 月 8 日，公司"国信 证券天士力 2017 年第 1 期员工持股定向资产管理计划"通过二级市场集中竞价 交易方式共计买入天士力股票 506,800 股，占公司当时总股本的比例为 0.0469%。 至此，公司已完成第一期员工持股计划标的股票的购买，锁定期自 2017 年 6 月 8 日起 12 个月。（详见公 ...

天士力医药集团股份有限公司（以下简称"公司"）于 2024 年 1 月向国家药 品监督管理局（以下简称"国家药监局"）药品审评中心递交枇杷清肺饮颗粒药 品注册申请并获得受理。现因该药品需进一步完善申报资料，公司向国家药监局 提交了撤回药品注册申请，待完成补充研究后将重新递交药品注册申请。公司于 近日收到国家药监局同意撤回注册申请的《药品注册申请终止通知书》，现将相 关信息披露如下： 证券代码：600535 证券简称：天士力 编号：临 2025-046 号 天士力医药集团股份有限公司 关于药品注册申请进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 受理号：CXZS2400002 药品生产企业：天士力医药集团股份有限公司 一、基本情况 药品名称：枇杷清肺饮颗粒 注册分类：中药 3.1 类 剂型：颗粒剂 功能主治：清肺经热，用于肺风酒刺，症见面鼻疙瘩，红赤肿痛，破出粉汁 或结屑等。 规格：每袋相当于饮片 24.62g 截至本公告日，公司对该项目累计研发投入为人民币 1,136.62 万元。 三、对公司的影响及风险提 ...

Core Viewpoint - Tianjin Tasly Pharmaceutical has withdrawn its application for the registration of Loquat Lung Cleansing Granules due to the need for further improvement of the application materials [1] Group 1: Company Actions - The company submitted the drug registration application to the National Medical Products Administration in January 2024 and received acceptance [1] - The company has submitted a request to withdraw the drug registration application and has received a notification from the National Medical Products Administration agreeing to the withdrawal [1] - The total R&D investment for this project amounts to 11.3662 million yuan [1] Group 2: Impact on Operations - The withdrawal of the application is not expected to have a significant impact on the company's current and future production operations and performance [1] - The pharmaceutical industry is characterized by high technology and high risk, with long R&D cycles and multiple influencing factors [1]

Group 1 - The board of directors of Tianjin Tasly Pharmaceutical Group Co., Ltd. held its 10th meeting of the 9th session on July 14, 2025, with 14 out of 15 directors present, ensuring the meeting's legality and effectiveness [1][2] - The board approved the "Guarantee Management System" with unanimous support, receiving 15 votes in favor and no opposition or abstentions [1] - The "Debt Financing and Liability Management System" was also approved unanimously, with 15 votes in favor and no opposition or abstentions [1] - The performance contract for the company and its management team for 2025 was recognized and approved by the board's nomination, remuneration, and assessment committee prior to the meeting [1] Group 2 - The proposal for senior management compensation and a three-year integration cash incentive plan was approved with 13 votes in favor, with no opposition or abstentions, while related directors recused themselves from the vote [2]